Polymer excipients for biopharmaceutical formulations
A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.
1. A polyacrylamide-based copolymer comprising:
a random copolymer consisting of:
a water-soluble carrier monomer selected from N-(3 methoxypropyl)acrylamide (MPAM) and 4-acryloylmorpholine (MORPH); and
a functional dopant monomer that is N-isopropylacrylamide (NIP),
wherein the random copolymer comprises from 10% to 28% by weight of NIP.
2. The copolymer of claim 1 , wherein the water-soluble carrier monomer is MORPH.
3. The copolymer of claim 2 , wherein the copolymer comprises from 20% to 26% by weight of NIP.
4. The copolymer of claim 1 , wherein the water-soluble carrier monomer is MPAM.
5. The copolymer of claim 1 , wherein the degree of polymerization is from 10 to 500.
6. The copolymer of claim 1 , wherein the molecular weight of the copolymer is from 1,000 to 50,000 g/mol.
7. The copolymer of claim 1 , wherein:
the degree of polymerization is from 20 to 200; and
the molecular weight of the copolymer is from 2,000 to 10,000 g/mol.
8. The copolymer of claim 1 , wherein
the average molecular weight (Mn) of the copolymer is from 1,000 g/mol to 30,000 g/mol; and
the degree of polymerization of the copolymer is from 10 to 250.
9. The copolymer of claim 8 , wherein the water-soluble carrier monomer is MORPH.
10. The copolymer of claim 9 , wherein the copolymer comprises from 20% to 26% by weight of NIP.
11. The copolymer of claim 9 , wherein the copolymer comprises 23% by weight of NIP.
12. The copolymer of claim 9 , wherein the copolymer comprises:
74% to 80% by weight of MORPH; and
20% to 26% by weight of NIP;
the average molecular weight (Mn) of the copolymer is from 1,000 g/mol to 5,000 g/mol; and
the degree of polymerization of the copolymer is 10 to 50.
13. The copolymer of claim 2 , wherein the copolymer comprises 77% by weight of MORPH and 23% by weight of NIP.
14. A polyacrylamide-based copolymer comprising:
a water-soluble carrier monomer selected from MPAM and MORPH; and
a functional dopant monomer that is N-phenylacrylamide (PHE).
15. The copolymer of claim 14 , wherein the water-soluble carrier monomer is MPAM.
16. The copolymer of claim 14 , wherein the water-soluble carrier monomer is MORPH.
17. The copolymer of claim 14 , wherein the copolymer comprises from 2% to 16% by weight of PHE.
18. The copolymer of claim 14 , wherein:
the degree of polymerization is from 10 to 500; and
the molecular weight of the copolymer is from 1,000 to 50,000 g/mol.
19. The copolymer of claim 18 , wherein:
the degree of polymerization is from 20 to 200; and
the molecular weight of the copolymer is from 2,000 to 10,000 g/mol.
20. A polyacrylamide-based copolymer consisting of:
a water-soluble carrier monomer that is N-(3-methoxypropyl)acrylamide (MPAM); and
a functional dopant monomer that is N-isopropylacrylamide (NIP).
21. The copolymer of claim 20 , wherein the copolymer is a random copolymer that comprises from 2% to 30% by weight of NIP.
22. The copolymer of claim 20 , wherein:
the degree of polymerization is from 10 to 500; and
the molecular weight of the copolymer is from 1,000 to 50,000 g/mol.
23. The copolymer of claim 22 , wherein:
the degree of polymerization is from 20 to 200; and
the molecular weight of the copolymer is from 2,000 to 10,000 g/mol.